Cerecin Inc. has successfully closed the first tranche of a series IIB financing with investors from South Korea, with SK Securities Co. Ltd. and KNT Investment LLC leading the round. Proceeds from the financing, of undisclosed value, will help the company advance clinical studies of its CER-0001 (tricaprilin) in migraine and infantile spasm.
Top-line phase III results showing Hutchmed Ltd.’s targeted therapy fruquintinib reduced the risks of death and disease progression by 34% and 68%, respectively, for patients with metastatic colorectal cancer could “lay a solid foundation for Hutchmed to initiate discussions with regulatory authorities worldwide,” a spokesperson of Hutchmed, told BioWorld.
Top-line phase III results showing Hutchmed Ltd.’s targeted therapy fruquintinib reduced the risks of death and disease progression by 34% and 68%, respectively, for patients with metastatic colorectal cancer could “lay a solid foundation for Hutchmed to initiate discussions with regulatory authorities worldwide,” a spokesperson of Hutchmed, told BioWorld.
A team of researchers at Toyohashi University of Technology in Japan have come up with a semiconductor sensor that can detect minute traces of biomarkers for infections or diseases.
China has upheld a recent ruling on a dispute between Chugai Pharmaceutical Co. Ltd. and Wenzhou Haihe Pharmaceutical Co. Ltd. over a generic form of an osteoporosis treatment. The move is seen as an indicator that patent protection for drugs has improved in China.
A research team at the Korea Advanced Institute of Science and Technology (KAIST) has developed tattoo ink made of liquid metal and carbon nanotubes that can work as a bioelectrode. This technology could translate to a tattoo that can function as a health-monitoring device.
Everest Medicines Ltd. has inked an agreement with Gilead Sciences Inc. to pass the latter’s subsidiary, Immunomedics Inc., exclusive rights to develop and commercialize Trodelvy (sacituzumab govitecan) in greater China, Singapore, Indonesia, Philippines, Vietnam, Thailand, Malaysia and Mongolia.
Everest Medicines Ltd. has inked an agreement with Gilead Sciences Inc. to pass the latter’s subsidiary, Immunomedics Inc., exclusive rights to develop and commercialize Trodelvy (sacituzumab govitecan) in greater China, Singapore, Indonesia, Philippines, Vietnam, Thailand, Malaysia and Mongolia. Everest stands to receive up to $455 million in total consideration, including $280 million up front and up to $175 million in potential milestone payments.
Beijing Longwood Valley Medical Technology Co. Ltd. (also known as Changmugu Medical) recently completed a series B financing of ¥540 million ($79.7 million) to advance its artificial intelligence (AI) medical products. It also signed a strategic partnership with Johnson & Johnson Medical China Ltd.
